These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3197751)

  • 61. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group.
    Thromb Res; 1989 Jul; 55(1):13-23. PubMed ID: 2528841
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ketanserin in the treatment of traumatic vasospastic disease.
    Larsen VH; Fabricius J; Nielsen G; Hansen KS
    Br Med J (Clin Res Ed); 1986 Sep; 293(6548):650-2. PubMed ID: 3092968
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
    Rembold CM; Ayers CR
    Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon.
    Belch JJ; Madhok R; Shaw B; Leiberman P; Sturrock RD; Forbes CD
    Lancet; 1985 May; 1(8439):1180-3. PubMed ID: 2860386
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathogenesis and treatment of Raynaud's phenomenon.
    Coffman JD
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():45-51. PubMed ID: 2285650
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
    Rustin MH; Almond NE; Beacham JA; Brooks RJ; Jones DP; Cooke ED; Dowd PM
    Br J Dermatol; 1987 Dec; 117(6):751-8. PubMed ID: 3322358
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.
    Amstein R; Fetkovska N; Ferracin F; Pletscher A; Bühler FR
    Drugs; 1988; 36 Suppl 1():61-6. PubMed ID: 2467792
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Hayward RA; Griffin MJ; Roath OS
    Br J Clin Pharmacol; 1991 Apr; 31(4):477-80. PubMed ID: 2049258
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Circulating dopamine in Raynaud's phenomenon.
    Marasini B; Biondi ML; Agostoni A
    Angiology; 1987 Dec; 38(12):878-82. PubMed ID: 3425974
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Isosorbide dinitrate ointment in Raynaud's disease.
    Diehm C; Müller-Bühl U; Mörl H
    Z Kardiol; 1983; 72 Suppl 3():185-7. PubMed ID: 6364591
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Plasma eicosanoids, platelet function and cold sensitivity.
    Wilkinson D; Vowden P; Gilks L; Latif AB; Rajah SM; Kester RC
    Br J Surg; 1989 Apr; 76(4):401-5. PubMed ID: 2720355
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.